Akebia Therapeutics Inc. (AX9)
XDUS
Closed
Aug 24, 2026
Day's Range
0.745852 wk Range
0.7086Overview - AX9 - Akebia Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
-133.04M
P/E (Trailing)
‪-37.67‬
Price / Book
‪8.11‬
EV / EBITDA
‪-5.35‬
Profitability
Gross Margin
‪78.78%‬
Profit Margin
‪83.29%‬
Operating Margin
‪8.66%‬
Return on Assets
‪-1.41%‬
Return on Equity
‪-16.39%‬
Ownership
Shares Outstanding
271.74M
Price stats
50-Day Avg
‪0.9877‬
200-Day Avg
‪1.12‬
Peers - AX9 - Akebia Therapeutics Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on XDUS.
- AX9XDUSAkebia Therapeutics Inc.-235.98%52-week change-39.05P/E (Trailing)‪83.29%‬Profit Margin
- IP40XDUSInnoCan Pharma Corporation+90.63%52-week change-5.40P/E (Trailing)‪89.92%‬Profit Margin
- PA8XDUSPaion AG+79.83%52-week change-0.74P/E (Trailing)‪94.10%‬Profit Margin
- 6CWXDUSCharlottes Web Holdings Inc.+74.27%52-week change-1.40P/E (Trailing)‪43.48%‬Profit Margin
- 20MPXDUSMountain Valley MD Holdings Inc.+68.45%52-week change-3.55P/E (Trailing)—Profit Margin
- HLSXDUSAIC Mines Limited+63.90%52-week change—P/E (Trailing)—Profit Margin
- 4KF0XDUSGlass House Brands Inc.+53.83%52-week change-14.00P/E (Trailing)‪42.28%‬Profit Margin
Profile Summary - AX9 - Akebia Therapeutics Inc.
About
Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients impacted by kidney disease. Its lead product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for treating anemia due to chronic kidney disease in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
